[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100499633":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":36,"collaborators":7,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":42,"sex":48,"minAge":49,"maxAge":7,"enrollmentInfo":50,"targetDuration":53,"studyType":54,"phases":7,"briefSummary":55,"conditions":56,"keywords":7,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Shanghai Jiao Tong University School of Medicine","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Xiong Ma, MD,PHD","Renji Hospital, School of Medicine, Shanghai Jiao Tong University","STUDY_CHAIR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Xiao Xiao, MD","CONTACT","021-68383104","xiaoxiao@renji.com",[20],{"facility":11,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"RECRUITING","Shanghai","Shanghai Municipality","200001","China","CN",{"type":28,"coordinates":29},"Point",[30,31],121.45806,31.22222,{"lat":31,"lon":30},[34],{"name":35,"role":16,"phone":17,"phoneExt":7,"email":18},"Xiao Xiao",{"type":37,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","maxiong","Director of Gastroenterology and Hepatology, Renji Hospital","100499633","autoimmune-hepatitis-cohort-in-china-100499633",false,"NCT05785793","Autoimmune Hepatitis Cohort in China","Clinical Characteristics and Outcomes of Autoimmune Hepatitis: a Retro-prospective Multicenter Cohort in China","CAMERA","Inclusion Criteria:\n\n* Age ≥ 14 years\n* Probable or definite diagnosis of autoimmune hepatitis according to the International Autoimmune Hepatitis Study Group criteria\n* Availability of all following essential parameters at the initial diagnosis of AIH: including alanine transaminase, aspartate aminotransferase, total bilirubin, alkaline phosphatase, immunoglobulin G, and platelet count\n* Provide informed consent\n\nExclusion Criteria:\n\n* Have a concomitant diagnosis of primary biliary sclerosis, primary sclerosing cholangitis, immunoglobulin G 4-related cholangitis\n* Have an active infection with hepatitis B virus, hepatitis C virus, hepatitis delta virus, HIV, cytomegalovirus, or Epstein-Barr virus\n* Have a concomitant diagnosis of hepatocellular carcinoma or other malignant diseases before the diagnosis of AIH\n* Considered ineligible to the enrollment in the clinical study by the researcher","ALL","14 Years",{"count":51,"type":52},1000,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this observational study is to describe the clinical features and long-term prognosis in patients diagnosed with autoimmune hepatitis (AIH) in China and assess the effectiveness and safety of AIH treatment options in a real-world setting.",[57],"Autoimmune Hepatitis","2023-03-26",{"date":60,"type":61},"2023-03-28","ACTUAL",{"date":63,"type":61},"2023-02-01",{"date":65,"type":52},"2028-02-01",{"name":5,"class":6},1]